Rating Change
Citigroup reiterated its Buy rating on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on November 09, 2026.
reiterateNASDAQ:LXRX
Citigroup Reiterates Buy Rating on Lexicon Pharmaceuticals, Inc. (LXRX)
Citigroup reiterated its Buy rating on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on November 09, 2026.
At publication ·
What changed
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) · reiterate
- Firm
- Citigroup
- Rating
- Buy to Buy
- Price at event
- $1.82
- Market capitalization
- $481.5M
At a glance
Key takeaways
- Citigroup maintained a Buy rating on Lexicon Pharmaceuticals (LXRX) on November 9, 2026, with the stock trading at $1.82 and a market cap of $481.5M.
- All 10 of the most recent analyst ratings for LXRX are Buy ratings, with no Hold or Sell ratings among recent coverage.
- Analyst ratings are one input among many for investment decisions and have mixed predictive power on their own.
- Significant changes in analyst consensus, such as multiple upgrades or downgrades in a short period, can be more meaningful signals than individual ratings.
Market Context
Lexicon Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $1.82 with a market capitalization of $481.5M.
Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Lexicon Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Lexicon Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 09, 2026 | Citigroup | Buy | N/A |
| Sep 28, 2026 | Cantor Fitzgerald | Overweight | N/A |
| May 11, 2026 | Citigroup | Buy | N/A |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | N/A |
| Mar 10, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LXRX Stock Page
Frequently Asked Questions
What does the Buy rating mean for LXRX?
A rating of Buy from Citigroup reflects the analyst's outlook on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LXRX forecast page.
Loading related coverage…
